Recently, several CPT analogs and TOP1 antibody–drug conjugates (ADCs) have been FDA‐approved for treating solid tumors.[36] Our work suggests that inhibition of TOP1 might be a promising target for ETV4‐dysregulated lung cancer. This evidence concerns the gene ETV4 and lung cancer.